BioGeneration Ventures (BGV) is a venture capital company, with a focus on early stage European biotech, medtech, and diagnostics companies. BGV has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class teams. The Company manages over €100 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together.
BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realisation for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit.
Historical successful investments include divestment of Dezima Pharma to Amgen for up to USD 1.55 billion in total deal value and in Acerta Pharma for up to USD 7 billion with a guaranteed payment of USD 4 billion. Both companies were co-founded by BGV in 2012 and 2013 respectively. The Acerta Pharma sale was the largest exit ever of a privately held European biotech company.
BGV is based in Naarden, The Netherlands, and closely collaborates with Forbion.
Location: Netherlands, North Holland, Naarden
Employees: 11-50
Founded date: 2006
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A
Portfolio 24
Date | Name | Website | Total Raised | Location |
25.02.2022 | Cision | prnewswire... | - | - |
25.02.2022 | VectorY | vectorytx.... | $178.32M | Netherland... |
25.02.2022 | Complement... | complement... | $84.66M | United Kin... |
25.02.2022 | Dunad | dunad.co.u... | - | - |
18.08.2021 | NewAmsterd... | newamsterd... | $377.6M | - |
18.08.2021 | Fibrocor | fibrocorth... | - | - |
18.08.2021 | Mironid® L... | mironid.co... | $6.31M | United Kin... |
18.08.2021 | NewAmsterd... | citryll.co... | $37.72M | - |
03.08.2021 | Dezima Pha... | investors.... | - | United Sta... |
03.08.2021 | Progentix ... | progentix.... | - | - |
Show more
Mentions in press and media 23
Date | Title | Description | Source |
12.03.2024 | Azafaros announces completion of 12-week Phase 2 RAINBOW stu... | Major milestone reached in bringing new treatment options to patients and their families Leiden, The... | forbion.co... |
02.10.2023 | 'The fundamentals are really strong': Why investors are stay... | While the biotech bull market hasn’t charged back in 2023 as many had hoped, European-focused ventur... | fiercebiot... |
19.07.2023 | Dutch biotech River BioMedics raises €2M to discover, develo... | Read this article in: Enschede-based River BioMedics, a Dutch biotech company focused on cardiac dru... | siliconcan... |
13.07.2023 | BioGeneration Ventures Closes BGV Fund V, at €150M | BioGeneration Ventures (BGV), a Naarden, The Netherlands-based early-stage VC in European biopharma,... | finsmes.co... |
11.05.2023 | Il mercato del Venture Capital ad aprile 2023 | Come è andato il mercato del Venture Capital ad aprile 2023? Facciamo insieme una carrellata delle s... | startup-ne... |
18.11.2022 | FundaMental Pharma launches with EUR 10 million in Seed fina... | November 17, 2022 | htgf.de/en... |
26.09.2022 | Amsterdam-based Phosphoenix bags funds to help blind people ... | Amsterdam-based Phosphoenix, a company that is working to help blind people regain functional vision... | siliconcan... |
01.10.2021 | BGV closes $110M fund | Benhamou Global Ventures has raised $110 million for its fourth flagship fund. The Palo Alto-based V... | pitchbook.... |
30.09.2021 | BGV closes fourth fund with $110M aimed at immigrant enterpr... | Silicon Valley-based venture capital (VC) firm Benhamou Global Ventures, known as BGV, closed its fo... | techcrunch... |
09.07.2020 | VarmX raises €32M in Series B financing to develop innovativ... | 08/07/2020 Press release VARMX RAISES €32 MILLION IN SERIES B FINANCING TO DEVELOP INNOVATIVE REVE... | webcapital... |
Show more